firing up my L2's
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OT: just heard " I will kill all of you , you killed my brother"
OT: Boston police scanner
http://tunein.com/radio/Boston-Police-Fire-and-EMS-Scanner-s146109/
VRTX: CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 18, 2013--
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from
a Phase 2 study of VX-661 and ivacaftor that showed statistically significant
improvements in lung function among adults with cystic fibrosis (CF) who have
two copies (homozygous) of the most common mutation in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene, known as F508del. The study
evaluated four dose levels of VX-661 (10, 30, 100 and 150 mg) dosed once daily
for 28 days in combination with ivacaftor (150 mg) dosed twice daily. The study
also evaluated a separate group of patients who received VX-661 (10, 30, 100
and 150 mg) dosed without ivacaftor for 28 days. Dose-dependent, mean relative
improvements in lung function (percent predicted forced expiratory volume in
one second; FEV(1) ), both within group and versus placebo, were observed
across the combination dosing groups. Patients in the 100 and 150 mg
combination dose groups showed statistically significant mean relative
improvements in lung function, versus placebo, of 9.0 percent (p=0.01) and 7.5
percent (p=0.02), respectively, at Day 28. In contrast, patients who received
placebo showed a 0.03 percent mean relative change in lung function at Day 28
(within-group). The mean relative FEV(1) across the combination dose groups
returned toward baseline during the post-treatment 28-day washout period.
VX-661 was generally well-tolerated, both as monotherapy and in combination
with ivacaftor, and most adverse events were mild to moderate in severity and
similar between the treatment groups and those who received placebo. Vertex
plans to conduct additional studies of VX-661 to further evaluate its potential
for late-stage development, pending regulatory discussions.
"This first study of VX-661 and ivacaftor provides further validation of the
strategy of combining a corrector and potentiator to improve lung function in
people with the most common type of cystic fibrosis," Peter Mueller, Ph.D.,
Chief Scientific Officer and Executive Vice President of Global Research and
Development at Vertex. "With these data and the recent initiation of a Phase 3
program for a combination of our lead CFTR corrector VX-809 with ivacaftor, we
are making significant progress toward our goal to help many more people with
CF."
Cystic fibrosis is caused by a defective or missing CFTR protein resulting
from mutations in the CFTR gene. In people with two copies of the most common
mutation in the CFTR gene, F508del, little to no CFTR protein reaches the cell
surface. VX-661, known as a CFTR corrector, is believed to help CFTR protein
reach the cell surface. Ivacaftor, known as a CFTR potentiator, keeps cell
surface CFTR protein channels open longer to increase the flow of salt and
water. Worldwide, nearly half of people with CF have two copies of the F508del
mutation and an additional one-third have one copy of the F508del mutation.
About the Study
The Phase 2 randomized, double-blind, placebo-controlled study treated 128
people with CF ages 18 and older with two copies of the F508del mutation. One
group of patients was randomized to receive either VX-661 (10, 30, 100 and 150
mg dosed once daily), or placebo, alone for 28 days. A separate group of
patients was randomized to receive the combination of VX-661 (10, 30, 100 and
150 mg dosed once daily) and ivacaftor (150 mg dosed twice daily), or placebo,
for 28 days. The primary endpoints of the study were safety, tolerability and
change in sweat chloride. Change in lung function (percent predicted forced
expiratory volume in one second; FEV(1) ) was measured as a secondary endpoint.
There were statistically significant mean absolute decreases in sweat
chloride, both within-group and versus placebo, across the combination and
monotherapy groups. These changes were generally modest and were variable
across the dose groups.
VX-661 was generally well-tolerated when dosed alone and in combination with
ivacaftor. The most common adverse events were pulmonary in nature. Most
adverse events were mild to moderate in severity and similar between the
treatment and placebo groups, and the types and frequency of adverse events
were similar between the treatment and placebo groups. The rate of serious
adverse events was also similar between the treatment groups and those who
received placebo.
ALGN: 4:05PM Align Tech beats by $0.03, beats on revs; guides Q2 below consensus (ALGN) : Reports Q1 (Mar) earnings of $0.26 per share, $0.03 better than the Capital IQ Consensus Estimate of $0.23; revenues rose 13.7% year/year to $153.6 mln vs the $149.14 mln consensus. Co issues downside guidance for Q2, sees EPS of $0.26-0.28 vs. $0.31 Capital IQ Consensus Estimate; sees Q2 revs of $153.6-157.4 mln vs. $159.17 mln Capital IQ Consensus Estimate.
Tanker AMD earnings amc, pc biz dyin'
Gapper ALGN earnings, lots of gaps on Q's
SanDisk Corp.'s (SNDK) first-quarter profit rose 45% as the flash-memory
maker said its sales of solid-state drives were gaining traction. The company
also raised its full-year revenue outlook, seeing $5.6 million to $5.75
billion, up from its previous projection of $5.3 billion to $5.6 billion.
NUGT: when are miners going BK en masse? Chart link back
Chanos negative article on US Tech:
http://finance.yahoo.com/blogs/daily-ticker/jim-chanos-stay-away-u-tech-firms-183534904.html
Even though Dell and HP have been starting to make huge acquisitions to gain a competitive advantage, they're doing a "very bad job" at it, Chanos argues.
“I am completely mystified as to what the buyout groups at Dell are seeing here because the business from a cash flow point of view, from an accounting point of view, is deteriorating right before your eyes and yet there seems to be a number of players who think this is the greatest thing since sliced bread," Chanos says.
UGLD (3x short Gold etf): just shorted a bunch at 36.35, chart a link back and check this tweet from Steve Liesman
@steveliesman 16m
Sure sounded like Bernanke saying a tapering of QE3 is sooner rather than later if jobs gains continue as they have.
re NUGT, GLD likely down due to good jobs #, reality that end of QE is at least likely in the next couple of years lol, jmo
Yeah he is. He's willing to risk a fortune to hurt Ackman.
Tanker RST earnings amc, such a terd
Gapper STMP Tanker ROVI both earnings amc sorry short post no charts
STVF seeking alpha article, likens the stock to ARNA
http://seekingalpha.com/article/1174671-what-do-stevia-first-and-arena-pharmaceuticals-have-in-common
STVF seeking alpha article, likens the stock to ARNA, wow
http://seekingalpha.com/article/1174671-what-do-stevia-first-and-arena-pharmaceuticals-have-in-common
omg...I remember COPI was among the group of stocks that a bunch of ihubbers got in hot water w/the sec about...back in 09 I think?
I think that's the cost of tuition for learning to trade...falling for these BS stories put out by sketchy companies...losing your money, then giving it a go another time
STSI I watched the sales pitch from agora, the guy actually admits visiting the company hq's and hanging out with the CEO
STSI: always an endless supply of dreamers in penny land
Gapper ACI earnings, last 2 q's been excellent
STSI yep stansberry made a lot of money teasing this as a wonder drug/neutraceutical to old timers, they told them to buy the stock and the neutraceutical if I recall lol
TLT and if it goes up so do mortgage rates if I'm not mistaken...might pose a problem for the housing market later this year.
Tanker TWIN earnings tues bmo
Gapper OMN earnings tues bmo
Tanker BTX same logic as yesterday
Yep just have to keep my momentum all year....unlike last year lol.
OT: 1. dunno what that is
2. 'spose not! :0)
Gapper BTX stansberry pump
hey DC, I've been golfin too much
OT: back in limited fashion again guys, unless I get bit by the ihub bug